CY2017010I2 - Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης - Google Patents
Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονηςInfo
- Publication number
- CY2017010I2 CY2017010I2 CY2017010C CY2017010C CY2017010I2 CY 2017010 I2 CY2017010 I2 CY 2017010I2 CY 2017010 C CY2017010 C CY 2017010C CY 2017010 C CY2017010 C CY 2017010C CY 2017010 I2 CY2017010 I2 CY 2017010I2
- Authority
- CY
- Cyprus
- Prior art keywords
- parathormone
- lowering
- levels
- therapeutic agents
- therapeutic
- Prior art date
Links
- 102000003982 Parathyroid hormone Human genes 0.000 title 1
- 108090000445 Parathyroid hormone Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000199 parathyroid hormone Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22969509P | 2009-07-29 | 2009-07-29 | |
| US25581609P | 2009-10-28 | 2009-10-28 | |
| US31363510P | 2010-03-12 | 2010-03-12 | |
| PCT/US2010/043792 WO2011014707A2 (en) | 2009-07-29 | 2010-07-29 | Therapeutic agents for reducing parathyroid hormone levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2017010I1 CY2017010I1 (el) | 2017-11-14 |
| CY2017010I2 true CY2017010I2 (el) | 2017-11-14 |
Family
ID=43527590
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101349T CY1118388T1 (el) | 2009-07-29 | 2016-12-27 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
| CY2017010C CY2017010I2 (el) | 2009-07-29 | 2017-03-16 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
| CY20191100579T CY1121922T1 (el) | 2009-07-29 | 2019-05-31 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101349T CY1118388T1 (el) | 2009-07-29 | 2016-12-27 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100579T CY1121922T1 (el) | 2009-07-29 | 2019-05-31 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
Country Status (30)
| Country | Link |
|---|---|
| US (10) | US8999932B2 (el) |
| EP (5) | EP3192520B1 (el) |
| JP (3) | JP5270799B2 (el) |
| KR (1) | KR101781841B1 (el) |
| CN (2) | CN107674114B (el) |
| AU (1) | AU2010278897B2 (el) |
| BR (1) | BR112012002143B8 (el) |
| CA (1) | CA2769525C (el) |
| CY (3) | CY1118388T1 (el) |
| DK (2) | DK3192520T3 (el) |
| ES (2) | ES2729051T3 (el) |
| FR (1) | FR17C1009I2 (el) |
| HK (1) | HK1167108A1 (el) |
| HR (2) | HRP20161614T1 (el) |
| HU (3) | HUE043838T2 (el) |
| IL (1) | IL217749A (el) |
| LT (3) | LT3192520T (el) |
| LU (1) | LUC00008I2 (el) |
| MX (1) | MX2012001213A (el) |
| NO (1) | NO2017021I1 (el) |
| NZ (1) | NZ597922A (el) |
| PL (2) | PL3192520T3 (el) |
| PT (2) | PT2459208T (el) |
| RU (1) | RU2557654C3 (el) |
| SG (2) | SG178143A1 (el) |
| SI (2) | SI2459208T1 (el) |
| SM (1) | SMT201700014B (el) |
| TW (1) | TWI520744B (el) |
| WO (1) | WO2011014707A2 (el) |
| ZA (1) | ZA201200726B (el) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101668421B (zh) * | 2006-11-16 | 2014-05-21 | 凯制药公司 | 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽 |
| TWI520744B (zh) | 2009-07-29 | 2016-02-11 | 凱宜製藥股份有限公司 | 減少副甲狀腺素量之治療劑 |
| JP5761173B2 (ja) | 2010-03-04 | 2015-08-12 | 味の素株式会社 | 糖尿病又は肥満症の予防又は治療剤 |
| PT2546231T (pt) | 2010-03-04 | 2019-02-06 | Ea Pharma Co Ltd | Derivado de alquilamina |
| JP5796570B2 (ja) | 2010-03-24 | 2015-10-21 | 味の素株式会社 | グルタミン酸エステル誘導体又はその塩 |
| WO2011126099A1 (ja) | 2010-04-02 | 2011-10-13 | 味の素株式会社 | 糖尿病又は肥満症の予防又は治療剤 |
| EP2717896B1 (en) * | 2011-06-08 | 2016-08-24 | Kai Pharmaceuticals, Inc. | Therapeutic agents for regulating serum phosphorus |
| WO2013071262A1 (en) * | 2011-11-10 | 2013-05-16 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
| AU2013249337A1 (en) * | 2012-04-17 | 2014-10-30 | Brown University | Neuroprotective composition and method of use |
| US20200354428A9 (en) | 2013-06-23 | 2020-11-12 | Wisconsin Alumni Research Foundation | Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles |
| SG11201510647TA (en) * | 2013-06-28 | 2016-01-28 | Amgen Inc | Stable liquid formulation of amg 416 (velcalcetide) |
| PT3126373T (pt) * | 2014-04-03 | 2020-04-24 | Amgen Inc | Método para a produção do amg 416 |
| CN105504012A (zh) * | 2014-09-30 | 2016-04-20 | 深圳翰宇药业股份有限公司 | 一种多肽的制备方法 |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| WO2016154580A1 (en) * | 2015-03-26 | 2016-09-29 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
| US9336841B1 (en) * | 2015-04-16 | 2016-05-10 | Taiwan Semiconductor Manufacturing Co., Ltd. | Pipeline register with data alignment therein |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| US10105375B2 (en) | 2016-08-30 | 2018-10-23 | Wisconsin Alumni Research Foundation | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism |
| EP3706781A4 (en) * | 2017-11-07 | 2021-07-21 | Alphacore Pharma LLC | METHODS OF TREATMENT AND PROTECTION AGAINST HEART DISEASE, CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS AND SYMPTOMS |
| WO2019124411A1 (ja) | 2017-12-20 | 2019-06-27 | Ｅａファーマ株式会社 | 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物 |
| AU2019370565A1 (en) * | 2018-11-02 | 2021-06-24 | Ampersand Biopharmaceuticals, Inc. | Management of risk of cation overload and electrolyte imbalance with topically applied buffers |
| EP3950058A4 (en) | 2019-04-03 | 2023-01-04 | EA Pharma Co., Ltd. | PHARMACEUTICAL COMPOSITION WITH FAVORABLE STABILITY |
| MX2022006892A (es) | 2019-12-09 | 2022-10-07 | Beijing Tuo Jie Biopharmaceutical Co Ltd | Compuesto agonista del receptor sensor de calcio y aplicación del mismo. |
| US20230223125A1 (en) * | 2020-05-04 | 2023-07-13 | University Of Louisville Research Foundation, Inc. | Artificial intelligence-based systems and methods for dosing of pharmacologic agents |
| WO2022052471A1 (zh) * | 2020-09-10 | 2022-03-17 | 陕西麦科奥特科技有限公司 | 双特异性融合多肽化合物 |
| US11359134B2 (en) | 2020-10-19 | 2022-06-14 | Saudi Arabian Oil Company | Treatment fluids and methods for recovering hydrocarbons from a subterranean formation |
| CN117500820A (zh) * | 2021-06-08 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
| CN117295510A (zh) * | 2021-06-08 | 2023-12-26 | 北京拓界生物医药科技有限公司 | 一种钙敏感受体激动剂的组合物及其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869473A (en) * | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| WO1992008476A1 (en) | 1990-11-07 | 1992-05-29 | The Scripps Research Institute | Peptides that inhibit platelet binding of adhesion molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| CA2145214A1 (en) | 1995-02-28 | 1996-08-29 | Rick E. Preddie | Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5688489A (en) | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| US6147186A (en) | 1996-07-31 | 2000-11-14 | The General Hospital Corporation | Parathyroid hormone-related peptide analogs |
| US5895368A (en) | 1996-09-23 | 1999-04-20 | Medisystems Technology Corporation | Blood set priming method and apparatus |
| US6165977A (en) | 1996-10-18 | 2000-12-26 | Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase C methods and compositions |
| US5955431A (en) * | 1997-02-05 | 1999-09-21 | Brigham And Women's Hospital, Inc. | Mast cell protease peptide inhibitors |
| CA2290443A1 (en) * | 1997-05-14 | 1998-11-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Peptide parathyroid hormone analogs |
| ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
| JP2000336099A (ja) * | 1999-05-27 | 2000-12-05 | Sekisui Chem Co Ltd | ペプチド及びｃ型肝炎抗体検出用試薬 |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| US20020068342A1 (en) * | 2000-02-09 | 2002-06-06 | Rami Khosravi | Novel nucleic acid and amino acid sequences and novel variants of alternative splicing |
| IL153378A0 (en) | 2000-07-18 | 2003-07-06 | Bone Care Internat Inc | STABILIZED 1alpha-HYDROXY VITAMIN D |
| DE10041126A1 (de) * | 2000-08-22 | 2002-04-04 | Aventis Res & Tech Gmbh & Co | DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen |
| US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| US20020168354A1 (en) | 2000-11-10 | 2002-11-14 | Daria Mochly-Rosen | psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia |
| US6855693B2 (en) | 2001-01-18 | 2005-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of δPKC |
| AU2002240312A1 (en) | 2001-02-08 | 2002-08-19 | Pankaj Paranjp | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates |
| US20030036627A1 (en) | 2001-02-16 | 2003-02-20 | Montelaro Ronald C. | Virus derived antimicrobial peptides |
| CA2439178C (en) | 2001-02-23 | 2013-06-04 | Polyphor Ltd. | Template-fixed peptidomimetics with antimicrobial activity |
| WO2003013543A1 (en) | 2001-08-08 | 2003-02-20 | Genomed, Llc | Treatment or prevention of acute renal failure |
| US6790833B2 (en) * | 2001-08-08 | 2004-09-14 | The Research Foundation Of The State University Of New York | Antifungal and antibacterial agents |
| US7060023B2 (en) | 2001-09-25 | 2006-06-13 | The Foundry Inc. | Pericardium reinforcing devices and methods of using them |
| JP2005287302A (ja) | 2002-04-03 | 2005-10-20 | Haruhiko Fujiwara | ポリペプチドの架橋方法 |
| AU2003299496A1 (en) | 2002-05-14 | 2004-05-25 | Bristol-Myers Squibb Company | Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof |
| ATE377023T1 (de) | 2003-11-05 | 2007-11-15 | Pevion Biotech Ltd | Zusammensetzungen, die von melittin abgeleitet sind und peptide enthalten, und verfahren zur potenzierung von immunreaktionen gegen target- antigene |
| EP1699813A2 (en) | 2003-12-11 | 2006-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific antagonists of protein kinase c |
| WO2005072340A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
| JP2008508294A (ja) * | 2004-07-27 | 2008-03-21 | ジェンザイム・コーポレイション | 骨の再生のためのチロトロピンの使用法 |
| US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| DE102005013846A1 (de) | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| KR100687932B1 (ko) * | 2005-08-09 | 2007-02-27 | 삼성전자주식회사 | 영상표시장치 및 영상표시방법 |
| JP2009511426A (ja) | 2005-08-30 | 2009-03-19 | アコロジックス インコーポレイティッド | ミネラルおよび骨格代謝の調節 |
| CN101668421B (zh) * | 2006-11-16 | 2014-05-21 | 凯制药公司 | 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽 |
| CN108948144A (zh) | 2007-01-19 | 2018-12-07 | 凯制药公司 | 肽组合物的修饰以提高稳定性和递送效率 |
| AU2008308679B2 (en) * | 2007-10-02 | 2015-01-29 | Marina Biotech, Inc. | Lipopeptides for delivery of nucleic acids |
| US8716437B2 (en) | 2007-12-07 | 2014-05-06 | Steven A. Goldstein | Identification of toxin ligands |
| US20090318351A1 (en) * | 2008-03-12 | 2009-12-24 | Kevin Grimes | Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist |
| TWI520744B (zh) | 2009-07-29 | 2016-02-11 | 凱宜製藥股份有限公司 | 減少副甲狀腺素量之治療劑 |
| EP2717896B1 (en) | 2011-06-08 | 2016-08-24 | Kai Pharmaceuticals, Inc. | Therapeutic agents for regulating serum phosphorus |
| WO2013071262A1 (en) | 2011-11-10 | 2013-05-16 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
-
2010
- 2010-07-29 TW TW099125105A patent/TWI520744B/zh active
- 2010-07-29 EP EP16190682.1A patent/EP3192520B1/en active Active
- 2010-07-29 DK DK16190682.1T patent/DK3192520T3/da active
- 2010-07-29 SG SG2012006185A patent/SG178143A1/en unknown
- 2010-07-29 WO PCT/US2010/043792 patent/WO2011014707A2/en active Application Filing
- 2010-07-29 HU HUE16190682A patent/HUE043838T2/hu unknown
- 2010-07-29 US US12/846,724 patent/US8999932B2/en active Active
- 2010-07-29 HU HUE10805078A patent/HUE030960T2/en unknown
- 2010-07-29 EP EP20209086.6A patent/EP3808363B1/en active Active
- 2010-07-29 PL PL16190682T patent/PL3192520T3/pl unknown
- 2010-07-29 NZ NZ597922A patent/NZ597922A/en unknown
- 2010-07-29 RU RU2012107428A patent/RU2557654C3/ru active
- 2010-07-29 KR KR1020127004785A patent/KR101781841B1/ko active IP Right Grant
- 2010-07-29 CN CN201710873189.9A patent/CN107674114B/zh active Active
- 2010-07-29 SI SI201031337A patent/SI2459208T1/sl unknown
- 2010-07-29 EP EP10805078.2A patent/EP2459208B1/en active Active
- 2010-07-29 JP JP2012523061A patent/JP5270799B2/ja active Active
- 2010-07-29 AU AU2010278897A patent/AU2010278897B2/en active Active
- 2010-07-29 BR BR112012002143A patent/BR112012002143B8/pt active IP Right Grant
- 2010-07-29 SI SI201031894T patent/SI3192520T1/sl unknown
- 2010-07-29 SG SG10201406921SA patent/SG10201406921SA/en unknown
- 2010-07-29 MX MX2012001213A patent/MX2012001213A/es active IP Right Grant
- 2010-07-29 PT PT108050782T patent/PT2459208T/pt unknown
- 2010-07-29 ES ES16190682T patent/ES2729051T3/es active Active
- 2010-07-29 PT PT16190682T patent/PT3192520T/pt unknown
- 2010-07-29 ES ES10805078.2T patent/ES2607954T3/es active Active
- 2010-07-29 LT LTEP16190682.1T patent/LT3192520T/lt unknown
- 2010-07-29 LT LTEP10805078.2T patent/LT2459208T/lt unknown
- 2010-07-29 DK DK10805078.2T patent/DK2459208T3/en active
- 2010-07-29 CA CA2769525A patent/CA2769525C/en active Active
- 2010-07-29 SM SM201700014T patent/SMT201700014B/it unknown
- 2010-07-29 EP EP19159337.5A patent/EP3539555B1/en active Active
- 2010-07-29 PL PL10805078T patent/PL2459208T3/pl unknown
- 2010-07-29 EP EP22193946.5A patent/EP4154900A1/en active Pending
- 2010-07-29 CN CN201080045024.9A patent/CN102711789B/zh active Active
-
2012
- 2012-01-26 IL IL217749A patent/IL217749A/en active Protection Beyond IP Right Term
- 2012-01-30 ZA ZA2012/00726A patent/ZA201200726B/en unknown
- 2012-02-02 US US13/365,213 patent/US8377880B2/en active Active
- 2012-08-14 HK HK12107946.6A patent/HK1167108A1/zh unknown
-
2013
- 2013-02-18 US US13/769,744 patent/US9278995B2/en active Active
- 2013-05-09 JP JP2013099331A patent/JP5764613B2/ja active Active
-
2014
- 2014-02-10 JP JP2014023488A patent/JP2014094967A/ja active Pending
-
2015
- 2015-03-04 US US14/639,020 patent/US9567370B2/en active Active
-
2016
- 2016-02-08 US US15/018,567 patent/US9701712B2/en active Active
- 2016-12-01 HR HRP20161614TT patent/HRP20161614T1/hr unknown
- 2016-12-27 CY CY20161101349T patent/CY1118388T1/el unknown
-
2017
- 2017-01-09 US US15/402,133 patent/US20170114095A1/en not_active Abandoned
- 2017-03-01 HU HUS1700008 patent/HUS1700008I1/hu unknown
- 2017-03-09 LU LU00008C patent/LUC00008I2/fr unknown
- 2017-03-10 LT LTPA2017007C patent/LTC2459208I2/lt unknown
- 2017-03-16 CY CY2017010C patent/CY2017010I2/el unknown
- 2017-03-17 FR FR17C1009C patent/FR17C1009I2/fr active Active
- 2017-05-05 NO NO2017021C patent/NO2017021I1/no unknown
- 2017-06-21 US US15/629,536 patent/US10280198B2/en active Active
-
2019
- 2019-03-11 US US16/298,902 patent/US20190194252A1/en not_active Abandoned
- 2019-05-17 HR HRP20190923TT patent/HRP20190923T1/hr unknown
- 2019-05-31 CY CY20191100579T patent/CY1121922T1/el unknown
-
2020
- 2020-09-02 US US17/010,773 patent/US20200399309A1/en not_active Abandoned
-
2022
- 2022-10-04 US US17/960,060 patent/US20240116983A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2017010I2 (el) | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης | |
| BRPI0916931A2 (pt) | agentes terapêuticos | |
| SMT201500088B (it) | Trattamento con pirfenidone per pazienti con funzione epatica atipica | |
| BRPI1011587A2 (pt) | compostos e composições terapèuticas | |
| ATE526024T1 (de) | Fluvoxamin vermeidende pirfenidontheraphy | |
| BR112013013311A2 (pt) | agente terapêutico de indução de citotoxicidade | |
| BRPI0915879A2 (pt) | dispositivos médicos temporariamente posicionáveis | |
| BRPI0808191A2 (pt) | dispositivos implantáveis híbridos terapêuticos | |
| DK2326651T3 (da) | Buprenorphinanaloger | |
| DK2144905T3 (da) | Terapeutiske midler | |
| DK2408807T3 (da) | Fremgangsmåde til terapeutisk anvendelse | |
| DK2330887T3 (da) | Behandlingsindretning | |
| DK3300729T3 (da) | Terapeutiske sammensætninger indeholdende macitentan | |
| BRPI0910534A2 (pt) | terapia antiviral | |
| UY33111A (es) | Jeringas | |
| BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
| BRPI0910722A2 (pt) | columbário | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| BRPI0818598A2 (pt) | agentes terapêuticos - 802 | |
| BRPI0920743A2 (pt) | ribonucleases terapeuticas | |
| BRPI1010778A2 (pt) | "escada dupla" | |
| BRPI0910931A2 (pt) | ciclopentanos substituídos terapêuticos | |
| BRPI0910991A2 (pt) | piperidinas substituídas como compostos terapêuticos | |
| DK2420219T3 (da) | Indgivelsesport | |
| BRPI1013903A2 (pt) | tratamentos terapêuticos utilizando centaquina |